



**GENFIT OBTAINS THE RENEWAL OF THE OSEO
“INNOVATIVE COMPANY” LABEL AND CONFIRMS
ITS ELIGIBILITY FOR FCPI MUTUAL FUNDS**

Lille (France), Cambridge (Massachusetts, United States), February 2nd, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces that its “Innovative Company” label has been renewed by the French public organization OSEO after a favorable review by the funding committee. This certification enables GENFIT to qualify for Fonds Communs de Placement pour l’Innovation (FCPI), mutual funds that benefit from tax incentives by investing in innovative technology companies.

The label acknowledges the Company’s major investments in Research and Development to offer innovative therapeutic solutions in the field of cardiometabolic and neurodegenerative diseases.

Laurent Lannoo, General Secretary of GENFIT, stated: “This certification rewards our permanent and relevant strategy for innovation in therapeutic areas where unmet needs remain significant. These investments have helped to position GENFIT as one of the key players particularly in the treatment of type 2 diabetes.”

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer’s...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT’s proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS (AVE0897) and SOLVAY (SLV341), are in the advanced stages of Phase I.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has about 130 employees, including over 100 scientists. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board
+33 (0)3 20 16 40 00

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.